Merck & Co., Inc.’s licensing agreement with the Medicines Patent Pool to provide global access to its investigational COVID-19 therapeutic molnupiravir is being praised by industry critics for its transparency and breadth. They view it as a model for future licensing of COVID products.
Merck and the United Nations-backed Medicines Patent Pool (MPP) announced the signing of the voluntary licensing agreement on 27 October,...





